@article{AMJ3932,
author = {Cornelius Engelmann and Rajiv Jalan},
title = {Non selective beta-blocker in cirrhosis: not ‘whether’ but ‘who and how’},
journal = {AME Medical Journal},
volume = {2},
number = {7},
year = {2017},
keywords = {},
abstract = {Non selective beta-blockers (NSBBs) have been used for decades in patients with liver cirrhosis to reduce portal pressure and the risk for portal hypertensive bleeding (1-3). International guidelines recommend NSBB as primary and secondary prophylaxis for variceal bleeding in cirrhosis (4).
Patients with liver cirrhosis and portal hypertension have a distinct pathophysiological feature dominated by a hyperdynamic circulation (5).},
issn = {2520-0518}, url = {https://amj.amegroups.org/article/view/3932}
}